Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer
Shihui Wang,Yi Wei,Zhouli Li,Jingya Xu,Yunfeng Zhou
DOI: https://doi.org/10.2147/BCTT.S380651
2022-10-14
Breast Cancer: Targets and Therapy
Abstract:Shihui Wang, Yi Wei, Zhouli Li, Jingya Xu, Yunfeng Zhou Department of Radiology, The First Affiliated Hospital of Wannan Medical College, Wuhu, People's Republic of China Correspondence: Yunfeng Zhou, Department of Radiology, The First Affiliated Hospital of Wannan Medical College, Wuhu, People's Republic of China, Tel +86 18110876440, Email Background: Histological grade is an important factor in the overall prognosis of patients with invasive breast cancer. Therefore, the non-invasive assessment of histological grade in breast cancer patients is an increasing concern for clinicians. We aimed to establish an MRI-based radiomics model for preoperative prediction of invasive breast cancer histological grade. Methods: We enrolled 901 patients with invasive breast cancer and pre-operative MRI. Patients were randomly divided into the training cohort (n=630) and validation cohort (n=271) with a ratio of 7:3. A radiomics signature was constructed by extracting radiomics features from MRI images and was developed according to multivariate logistic regression analysis. The diagnostic performance of the radiomics model was assessed using receiver operating characteristic (ROC) curve analysis. Results: Of the 901 patients, 618 (68.6%) were histological grade 1 or 2 while 283 (31.4%) were histological grade 3. The area under the ROC curve (AUC) of the radiomics model for the prediction of the histological grade was 0.761 (95% CI 0.728– 0.794) in the training cohort and 0.722 (95% CI 0.664– 0.777) in the validation cohort. The decision curve analysis (DCA) demonstrated the radiomics model's clinical application value. Conclusion: This is a preliminary study suggesting that the development of an MRI-based radiomics model can predict the histological grade of invasive breast cancer. Keywords: breast cancer, histologic grade, magnetic resonance imaging, radiomics, signature Breast cancer is the most prevalent malignancy among women worldwide, accounting for almost 25% of all cancer cases in women. It is also the leading cause of cancer-related deaths in women worldwide. 1 Studies have shown that tumor histological grade is an independent prognostic factor in specific subgroups of breast cancer patients, including estrogen receptor positivity, 2 and lymph node metastasis. 3 Invasive ductal carcinoma (IDC), the most common histological type of breast cancer, accounts for approximately 80% of all breast cancers. Therefore, accurate identification of tumor's histological grade in the IDC can provide a useful guide to the prognosis. Magnetic resonance imaging (MRI) has been widely used in the study of breast cancer. Studies have shown that radiological analysis of MRI may help predict breast cancer subtypes, 4–6 neoadjuvant chemotherapy responses, 7,8 Ki-67 expression level, 9–11 pathological stage, 12 histological grade, 11,13,14 tumor malignancy, 15 and breast cancer recurrence. 16,17 The eighth edition of the cancer staging system of the American Joint Committee on Cancer (AJCC), combined histological grade with anatomical staging to determine the clinical prognostic stage, where histological grade 3 luminal carcinoma is one stage higher than its anatomical stage. 14,18 Therefore, we wish to distinguish histological grade 3 tumors from grade 1 or 2 tumors. However, to our knowledge, we used the largest sample size with effective predictors to develop and validate an MRI-based radiomics model for preoperative prediction of invasive breast cancer histological grade. Patients were collected from The Cancer Imaging Archive (TCIA; http://www.cancerimagingarchive.net/ ) datasets. 19 , 922 patients whose pre-operative MRI acquired from 1 January 2000 to 23 March 2014 with post-operative pathology confirmed invasive breast cancer. Patients with prior breast surgery, history of breast cancer, or neoadjuvant therapy before the MRI acquisition were excluded. 901 patients were eventually included in this study, due to the lack of histological grade information for 21 patients. Patients were randomly divided into the training cohort (n=630) and validation cohort (n=271) with a ratio of 7:3. The study flow diagram is shown in Figure 1. Figure 1 The flow diagram of the study. For the patients included in this study, cross-sectional breast MRI images were acquired in the prone position using a 1.5T or 3T scanner. Detailed scanner-related information and MR acquisition parameters are shown in the Tables S1 and S2 , respectively. The following sequences were acquired by MRI: a non-fat-saturated T1-weighted sequence, a fat-saturated gradient-echo T1-weighted enhancement sequence, and four post-enhanceme -Abstract Truncated-